Senti Biosciences Holdings (SNTI) Accounts Payables (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Accounts Payables of $2.9 million for Q4 2025, up 102.41% year-over-year from $1.5 million in Q4 2024, and up 66.18% quarter-over-quarter from $1.8 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Accounts Payables (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Accounts Payables history runs 5 years deep, the most recent figure standing at $2.9 million for Q4 2025.
- In Q4 2025, Accounts Payables rose 102.41% year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $2.9 million (up 102.41% YoY), while the FY2025 annual figure was $2.9 million, up 102.41% from the prior year.
- Accounts Payables for Q4 2025 stood at $2.9 million, up from $1.8 million in the prior quarter.
- The five-year high for Accounts Payables was $5.8 million in Q2 2022, with the low at $28.0 in Q1 2021.
- The 5-year median for Accounts Payables is $1.6 million (2025), against an average of $1.8 million.
- Peak annual rise in Accounts Payables reached 2079900.0% in 2022, while the deepest fall reached 73.59% in 2022.
- Senti Biosciences Holdings' Accounts Payables stood at $5.2 million in 2021, then slumped by 73.59% to $1.4 million in 2022, then declined by 8.76% to $1.2 million in 2023, then increased by 16.32% to $1.5 million in 2024, then soared by 102.41% to $2.9 million in 2025.
- Business Quant data shows SNTI's Accounts Payables at $2.9 million in Q4 2025, $1.8 million in Q3 2025, and $1.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.02 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | 793,000.00 |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | 1.99 Mn |
| Jun 30, 2023 | 2.59 Mn |
| Mar 31, 2023 | 2.58 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 1.77 Mn |
| Jun 30, 2022 | 5.76 Mn |
| Dec 31, 2021 | 5.19 Mn |
| Sep 30, 2021 | 85.00 |
| Jun 30, 2021 | 4,513.00 |
| Mar 31, 2021 | 28.00 |